The Georgia Immunoengineering Consortium's goal is to impact human health, in a personalized and predictive manner, through the application of innovative immune technologies to clinically relevant problems. Disease targets currently being investigated by GIEC Researchers include infectious diseases, inflammation and autoimmune disorders such as diabetes and lupus; improving immune regeneration therapy; cancer; other inflammatory conditions such as device-associated infection, arthritis and inflammatory bowel disease.
In order to address these Grand Challenges, researchers at Georgia Tech and Emory focus on a broad range of scientific areas including:
ImmunoEngineering rests on knowledge of how the immune system functions and malfunctions. Researchers at Georgia Tech and Emory investigate pathogen and autoimmune self-antigen recognition by T- and B-cells of the adaptive immunity, the trafficking of cells through blood and lymphatic vasculatures, signaling events that control the key functions of antigen-presenting dendritic cells and their interactions with biomaterials.
Figure 1 illustrates how these focus areas interact with each other.